# Chondrial Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chondrial-therapeutics

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.chondrialtherapeutics.com
- Total disclosed funding: $23M
- Latest round: Series A (Feb 1, 2017)
- Investors on record: 1

## About

Chondrial Therapeutics, Inc. focuses on developing innovative therapies for rare diseases by utilizing a proprietary intracellular delivery technology to address significant unmet medical needs in patient populations.Founded in 2013 in the United States, Chondrial Therapeutics, Inc. is engaged in creating novel treatments for rare genetic disorders. The company has not undergone any notable business pivots or changes. It has received a total of USD 3.20 mn in funding since its inception, with its most recent investment round occurring on May 20, 2019. Chondrial Therapeutics was created by individuals committed to addressing complex healthcare challenges and does not operate as a subsidiary of any parent company.Chondrial Therapeutics specializes in developing innovative treatments for rare diseases utilizing a proprietary intracellular delivery platform that facilitates the direct delivery of proteins and therapeutic molecules into cells. Its lead candidate, nomlabofusp (previously CTI-1601), aims to deliver human frataxin to patients with Friedreich’s ataxia, a rare genetic disorder that leads to progressive neurological decline. Currently in Phase 2 clinical trials, nomlabofusp seeks to improve patient quality of life. The company also plans to expand its platform by designing additional fusion proteins to address other rare conditions associated with intracellular protein deficiencies, targeting primarily North American and European markets.Chondrial Therapeutics' revenue model is structured around the development and potential commercialization of its lead product, nomlabofusp, alongside future offerings from its delivery platform. The company may engage in strategic partnerships with various stakeholders, including pharmaceutical distributors and healthcare providers, to enhance its market presence. Revenue generation is expected to stem from licensing agreements that grant production or commercialization rights to other firms, as well as direct sales to healthcare facilities upon obtaining regulatory approval. Its client base primarily consists of specialized medical practitioners and institutions focusing on rare diseases with specific therapeutic needs.Chondrial Therapeutics is focused on advancing its lead product, nomlabofusp, through its ongoing Phase 2 clinical trials. The company is strategically planning to expand its market reach into additional regions within North America and Europe by leveraging its recent funding of USD 3.20 mn raised in May 2019. This funding will support the continued development of nomlabofusp as well as initiatives to develop further fusion proteins targeting other rare diseases. The overall strategy emphasizes building partnerships within the healthcare ecosystem to facilitate the adoption of their innovative therapies.

## Funding rounds

- Series A, Feb 1, 2017, $23M — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A